Sensei Biotherapeutics acquires Faeth Therapeutics for $200 million Feb 18, 2026 08:01AM
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement Feb 18, 2026 08:00AM
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference Nov 27, 2024 04:05PM
Citi Resumes Sensei Biotherapeutics (SNSE) at Buy, 'Initial SNS-101 Efficacy Data at ASCO Suggest Early Clinical Activity' Jun 3, 2024 02:00PM
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences Aug 30, 2023 07:30AM


Feb 16, 2023 07:30AM Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit
Aug 23, 2022 07:30AM Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
Feb 11, 2022 07:30AM Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit
Aug 2, 2021 08:01AM Sensei Biotherapeutics (SNSE) Appoints Kristian Humer to its Board
Aug 2, 2021 08:01AM Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
Aug 2, 2021 08:01AM Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
Feb 10, 2021 04:55PM Sensei Biotherapeutics Announces Closing of Initial Public Offering
Feb 4, 2021 12:03PM Sensei Biotherapeutics (SNSE) IPO Opens 30% Higher
Feb 4, 2021 06:30AM Sensei Biotherapeutics Inc. (SNSE) Prices 7M Share Upsized IPO at $19/Sh
Feb 3, 2021 08:44PM Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering